After CAR-T treatment, the benefit is not significant, and it is difficult to enroll.
MM
The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Multiple Myeloma
Sponsor study identifier
interventional
2
1 country
1
Study Start
March 1, 2018
Actual (reported)Primary Completion
January 31, 2020
Actual (reported)Study Completion
January 31, 2020
Actual (reported)Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy.The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, and several clinical trials have been reported in the treatment of multiple myeloma with CAR-T cells.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 1, 2018
Actual (reported)March 15, 2018
Actual (reported)March 22, 2018
Actual (reported)January 31, 2020
Actual (reported)January 31, 2020
Actual (reported)Adverse events that Are related to treatment
Determine the toxicity profile of the BCMA/CD138/CD38/CD56-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0
2 years
Estimate 2 year overall survival(OS) after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment
2 years
Estimate 2 year relapse rate after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment
2 years
Estimate 2 year progression free survival after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment
2 years
In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.
one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Southern Medical University Zhujiang Hospital
Guangdong, Guangdong, 510000, China
Yanjie He
Zhujiang Hospital
2 participants (actual enrollment reported by the registry).
First Submitted
March 15, 2018
First Posted
March 22, 2018
Study Start
March 1, 2018
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
January 31, 2020
Actual (reported)Study Completion
January 31, 2020
Actual (reported)Last Updated
March 15, 2024
Record last verified: 2021-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: